INTRODUCTION
The anthracycline antibiotics daunomycin and 14-hydroxydaunomycin (adriamycin, ADR) have been shown to be very effective in the treatment of a number of malignancies (1,2). Besides the non--specific side effects of cytostatic agents, adriamycin exerts a specific toxic activity on the heart which may eventually lead to a life-threatening congestive heart failure when a cumulative dose of 550 mg/m2 has been exceeded (1,2). To effect a decrease in cardiotoxicity we are developing adriamycin-polymer conjugates which are not taken up by heart muscle cells but are readily incorporated in tumor cells. After internalization of a macromolecular substance by endocytosis a phagosome is formed which is then fused with a lysozome (Fig. 1) . The substance is then exposed to many digestive enzymes at an acidic pH (4-5) ( 3 ) . We have concentrated on the use of poly(a-L-glutamic acid)(PGA) as a carrier, because this polymer can readily be degraded by lysozomal enzymes and is rather plasma--stable. After partial derivatization the conjugate will be water--soluble owing to residual carboxylic acid groups.
RESULTS AND DISCUSSION
The adriamycin moiety was covalently bound to PGA with various labile linkages including acylhydrazone ( Fig. 2 ) and amide either without or with various peptide spacers (Fig. 3 ) . Details about the syntheses of these conjugates will be described elsewhere ( 4 , 5 ) . The cytotoxic activity of polymeric conjugates with either complex--bound or covalently-bound adriamycin was evaluated using in vitro Ll2lO clonogenic and B16 melanoma liquid assays (Table 1 ). These data indicate that adriamycin when complexed or linked to the carrier with an acylhydrazone bond at C-13 retains a significant cytotoxicity. The latter type of covalent bond appears promising for adriamycin prodrugs, although the polymeric conjugate as well as the acylhydrazide tend to become insoluble on standing for reasons still under study. Amide-bound prodrugs of adriamycin are found to be stable in plasma for at least 4 8 hours in accordance with their possible applicability as an endocellular release system. The cytotoxicity of these conjugates can be improved by the use of peptide spacers but remains relatively low. The data suggest that 
